# Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）

> **NCT04459611** · PHASE2 · UNKNOWN · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 60 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** sintilimab
- **DRUG:** pemetrexed
- **DRUG:** Carboplatin
- **DRUG:** albumin-bound paclitaxel

## Key facts

- **NCT ID:** NCT04459611
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-01
- **Primary completion:** 2021-11-01
- **Final completion:** 2023-07-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2022-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04459611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04459611, "Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04459611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*